Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Lincoln Pharmaceuticals Ltd Performance

Today's Low
550.05
arrowIcon
Today's High
575.00
52 Wk Low
365.25
arrowIcon
52 Wk High
755.15


Open

554.6

Traded Value (Cr)

2.12 Cr

Prev. Close

551.8

VWAP

563.38

Volume

36,876

Face Value

10

Lincoln Pharmaceuticals Ltd Fundamentals

Market Cap
₹ 1,140 Cr
P/E Ratio (TTM)
13.06
P/B Ratio
2.09
Debt to Equity
0.00
ROE
14.81 %
EPS (TTM)
43.57
Dividend Yield
0.26%
Book Value
272.59

Click here to know more about Fundamentals

Lincoln Pharmaceuticals Ltd Financials

Lincoln Pharmaceuticals Ltd Financials

Lincoln Pharmaceuticals Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 49.53 % 49.80 % 50.53 % 48.67 %
Retail 37.36 % 37.78 % 37.47 % 37.32 %
Others 9.18 % 9.19 % 9.41 % 12.26 %
FII 3.93 % 3.23 % 2.59 % 1.74 %
Mutual Funds 0.00 % 0.00 % 0.00 % 0.00 %

Promoters

49.53%

Retail

37.36%

Others

9.18%

FII

3.93%

Mutual Funds

0.00%

Promoters

49.80%

Retail

37.78%

Others

9.19%

FII

3.23%

Mutual Funds

0.00%

Promoters

50.53%

Retail

37.47%

Others

9.41%

FII

2.59%

Mutual Funds

0.00%

Promoters

48.67%

Retail

37.32%

Others

12.26%

FII

1.74%

Mutual Funds

0.00%

Resistance and Support

₹587.58

PIVOT

resistance-arrow
Resistance
First Resistance₹594.067
Second Resistance₹602.433
Third Resistance₹608.917
support-arrow
Support
First Resistance₹579.217
Second Resistance₹572.733
Third Resistance₹564.367
RSI37.216
MACD-6.574
ADX20.906
CCI-207.618

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day36,87622,17560.13
Week34,31020,79661.53
1 Month33,96321,66861.04
6 Months35,01023,12766.06

About Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals Limited, promoted by Mahendra G Patel, Rajnikant G Patel and Hasmukhbhai I Patel, as a Partnership Firm in Jan 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. '95. All the assets and business of the erstwhile partnership were transferred to the Company. The Company is engaged in the business of manufacturing and trading of pharmaceutical products. The company was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982. It then set up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups and, ointments. It is also getting its products manufactured on loan licence basis from other manufacturers to meet the demand of small volume parenterals. The company has set up a modern formulation manufacturing plant at Khatraj (Mehsana district), Gujarat, to manufacture small volume parenterals like dry powder injectables, liquid vial, liquid ampoules and eye drops and expand its production capacities of the existing products. It is also in the process of establishing a fully equipped laboratory to undertake in-house testing of its products for better quality control and R&D. It came out with a public issue in Feb.'96 to part-finance its project. The Company launched Next Generation Progesterone Therapy 'ProlinSpray' during the year 2018. During the year 2021-22, Lincoln Parenteral Limited (Transferor Company), an erstwhile subsidiary, merged with Lincoln Pharmaceuticals Limited (the Transferee Company) through the Scheme of Amalgamation and consequent to this, the Transferor Company ceases to be the subsidiary of the Company. The Company acquired a plant in Mehsana, Gujarat to launch Cephalosporin products in 2022.

Managing Director

Mahendra G Patel

Founded

1995

NSE Symbol

LINCOLN

Lincoln Pharmaceuticals Ltd Management

NameDesignation
Kishorbhai M ShahChairman (Non-Executive)
Mahendra G PatelManaging Director
Hasmukhbhai I PatelWhole-time Director
Pirabhai R SutharIndependent Director
Munjal Mahendrabhai PatelWhole-time Director
Aashish R PatelWhole-time Director
Meha PatelIndependent Director
Saurin J ParikhIndependent Director
Rajnikant G PatelDirector
Anand Arvindbhai PatelWhole-time Director
Trusha ShahCompany Sec. & Compli. Officer

Lincoln Pharmaceuticals Ltd News

Lincoln Pharmaceuticals to announce Quarterly Result
On 16 May 2024
Lincoln Pharmaceuticals consolidated net profit rises 29.75% in the December 2023 quarter
Sales rise 9.48% to Rs 146.45 crore
Lincoln Pharmaceuticals to convene board meeting
On 8 February 2024
Lincoln Pharmaceuticals consolidated net profit rises 16.62% in the September 2023 quarter
Sales rise 10.94% to Rs 155.99 crore
Lincoln Pharmaceuticals announces board meeting date
On 2 November 2023
Lincoln Pharmaceuticals to conduct AGM
On 30 September 2023
Lincoln Pharmaceuticals consolidated net profit rises 26.65% in the June 2023 quarter
Sales rise 9.84% to Rs 135.62 crore
Lincoln Pharmaceuticals to announce Quarterly Result
On 10 August 2023
Lincoln Pharmaceuticals to announce Quarterly Result
On 10 August 2023
Board of Lincoln Pharmaceuticals recommends final dividend
Of Rs 1.5 per share

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,61,471 Cr
₹ 1,506.55
(0.80 %)
87.73
CIPLA₹ 1,08,154 Cr
₹ 1,339.55
(-1.42 %)
29.12
DIVISLAB₹ 1,00,705 Cr
₹ 3,793.50
(0.09 %)
73.80
ZYDUSLIFE₹ 98,827 Cr
₹ 982.15
(1.44 %)
36.80
DRREDDY₹ 98,773 Cr
₹ 5,921.00
(0.74 %)
22.73

Lincoln Pharmaceuticals Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Lincoln Pharmaceuticals Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Lincoln Pharmaceuticals Ltd's share price is ₹570.10 as of May 10, 2024

Lincoln Pharmaceuticals Ltd's P/E ratio is 13.06 times as of May 10, 2024.

Lincoln Pharmaceuticals Ltd's most recent financial reports indicate a price-to-book ratio of 2.09, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Lincoln Pharmaceuticals Ltd's market is 1,140 Cr as on May 10, 2024.

The current financial records of Lincoln Pharmaceuticals Ltd show a 14.81% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Lincoln Pharmaceuticals Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Lincoln Pharmaceuticals Ltd's 52-week high and low as of May 10, 2024 are ₹575 and ₹550.05 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Lincoln Pharmaceuticals Ltd stands at 49.53%. During the same period, Institutional Investors have shown a slight increase in their holdings, rising from 3.23% to 3.93%.